BioSpace News Archive

Summit Medical Center is proud to announce that it has achieved the distinguished Gold Seal of Approval® for Advanced Total Hip and Knee Replacement Certification from The Joint Commission, the premier healthcare quality improvement and accrediting body in the nation.

Ocean Biomedical, Inc. and Virion Therapeutics, LLC announced they have entered into a joint venture to accelerate and expand Virion’s clinical-stage program and pipeline, with the goal of finding cures for patients with cancer and chronic infectious diseases.

Longeveron Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of Class A common stock.

Annovis Bio, Inc. today announced that the independent statistical group concluded that its Phase 2/3 AD study was sufficiently powered to continue as originally planned without the addition of patients.

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced the completion of enrollment in the Phase 1 study of INB-100 in leukemia patients and the initiation of patient enrollment in the Phase 2 clinical trial evaluating INB-400 in newly diagnosed glioblastoma multiforme (GBM).

Adagene Inc. today announced its poster presentation at the SITC 38th Annual Meeting taking place November 1-5, 2023 in San Diego.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, October 26, 2023, to report its third quarter financial results and provide a corporate update.

Onconova Therapeutics, Inc. announced that a late-breaking abstract studying rigosertib in patients with recessive dystrophic epidermolysis bullosa, associated with advanced/metastatic squamous cell carcinoma, will be presented in the Late Breaking News session at the EADV in Berlin, Germany.

Akeso, Inc. (9926.HK) (“Akeso”) announced that the results of the multicenter, open-label Phase Ib/II clinical trial (COMPASSION-03/AK104-201) for cadonilimab (PD-1/CTLA-4 bispecific antibody), the globally first bispecific IO drug used to treat advanced solid tumors, have been published in the October 2 issue of The Lancet Oncology.

Bracco Imaging S.p.A. received notification that the CHMP of the EMA has adopted a positive opinion recommending approval of Vueway® solution for injection for magnetic resonance imaging for use in adult and pediatric patients aged 2 years and older with magnetic resonance imaging of the CNS and several body organs.